January 20, 2016
A California federal judge on Wednesday ended a suit in which Allergan Inc. alleged that Ferrum Ferro Capital LLC's bid to invalidate a patent for a glaucoma drug under the America Invents Act amounted to extortion, after previously finding no subject matter jurisdiction.
November 18, 2015
Allergan Inc. has asked a California federal judge to reject the contention that its extortion claims are preempted by federal law in a suit seeking to block Ferrum Ferro Capital LLC's bid to invalidate a patent for a glaucoma drug, saying Ferrum already missed its chance to make that argument.
September 15, 2015
Allergan Inc. fought to keep its suit alleging Ferrum Ferro Capital LLC's bid to invalidate a patent for a glaucoma drug under the America Invents Act amounts to extortion in California federal court Monday, arguing the issue was vital to establish authority over "for-profit" inter partes reviews.
August 11, 2015
Ferrum Ferro Capital LLC urged a California federal judge on Monday to toss a lawsuit by Allergan Inc. that calls the venture capital fund's attempt to invalidate a patent on Allergan's glaucoma drug Combigan extortion, saying the suit is retaliation and violates California's anti-SLAPP statutes.
June 24, 2015
Allergan Inc. has sued Ferrum Ferro Capital LLC in California federal court, claiming the venture fund's attempt to invalidate a patent on Allergan's glaucoma drug Combigan under the America Invents Act is "extortion, pure and simple."